# US 2017/0362296 A1 · Peptides based on the transmembrane domain of a toll-like receptor (tlr) for treatment of tlr-mediated diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0362296 A1
- Document ID: US20170362296A1
- Status: Published application
- Kind: A1
- Application number: 15/696,206
- Filed: 2017-09-06
- Published: 2017-12-21
- Earliest claimed: 2010-07-19
- Assignees: Yeda Research and Development Co. Ltd.
- Applicants: Yeda Research and Development Co. Ltd.
- Inventors: Yechiel SHAI; Avner FINK; Eliran-Moshe REUVEN; Liraz GALIA
- Web page: https://patentgrep.com/patent/US20170362296A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61K 38/03: Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- A61K 38/04: Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34 {; protease inhibitors A61K38/55})
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/08: of the prostate
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 4/00: Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Peptides are provided that are capable of inhibiting cell activation mediated by a Toll-like receptor (TLR) selected from TLR 1, 2, 4 or 6, said peptide comprising a sequence consisting of, or found within, the sequence of the transmembrane domain of a TLR selected from TLR 1, 2, 4 or 6 and optionally cytoplasmic and extracellular regions flanking the transmembrane domain. These peptides as well as pharmaceutical composition comprising them are useful for the treatment of TLR-mediated disease.

## Claims

### Claim 1

A synthetic peptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 41-74, said amino acid sequence being linked at its N- and/or C-termini to an additional one to four positively charged amino acid residues, wherein said synthetic peptide inhibits cell activation mediated by a TLR.

### Claim 2 (depends on 1)

The synthetic peptide according to claim 1, wherein said peptide comprises at most 30 amino acid residues.

### Claim 3 (depends on 1)

The synthetic peptide according to claim 1, wherein said positively charged amino acid is selected from the group consisting of lysine, arginine, histidine and ornithine.

### Claim 4 (depends on 3)

The synthetic peptide according to claim 3, wherein one or two lysine residues are added to one or both of the N or C termini.

### Claim 5 (depends on 1)

The synthetic peptide according to claim 1, wherein said amino acid sequence comprises at least one D amino acid.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising the synthetic peptide according to claim 1, and a pharmaceutically acceptable carrier.

### Claim 7

A method for the treatment of a TLR-mediated disease, the method comprising administering to a patient suffering from said TLR-mediated disease an effective amount of a synthetic peptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 1-121.

### Claim 8 (depends on 7)

The method according to claim 7, wherein said TLR-mediated disease is an inflammation or cancer.

### Claim 9 (depends on 8)

The method according to claim 8, wherein said inflammation is acute inflammation.

### Claim 10 (depends on 8)

The method according to claim 8, wherein said cancer is selected from the group consisting of prostate cancer, gastric carcinoma, colon cancer, hepatocellular carcinoma, epithelial ovarian cancer, cervical squamous cell carcinomas, breast cancer, lung cancer, melanoma and neuroblastoma.

### Claim 11 (depends on 7)

The method according to claim 7, wherein said TLR-mediated disease is selected from the group consisting of a septic shock, a systemic inflammatory response syndrome (SIRS), an acute inflammation, a post ischemic reperfusion injury, an inflammatory bowel disease, an exacerbation of latent or active infection, a congestive heart failure, an autoimmune disease, a chronic obstructive pulmonary disease, a predisposition to pulmonary bacterial infection, a congestive heart failure with pulmonary edema, a rheumatoid disease, a degenerative disease, a neurodegenerative disease, a fibrotic disease, a cachexia, a graft rejection, a radiation damage, an asthma and a cancer.
